StockNews.AI
RGLS
StockNews.AI
107 days

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

1. Regulus Therapeutics is proposed to be sold to Novartis for $7.00 per share. 2. Legal investigation into the sale may impact shareholder outcomes.

2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition price of $7.00 per share is higher than current trading prices, indicating potential upside for shareholders. Historical cases show similar acquisitions can boost stock prices pre-sale completion.

How important is it?

This article provides critical information about an acquisition, which can significantly influence RGLS's stock price and shareholder interests.

Why Short Term?

The immediate price reaction is likely to be felt quickly due to the acquisition news. Similar past acquisitions in biotech typically cause short-term price movements.

Related Companies

NVSTMRNAEDIT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Regulus Therapeutics Inc. (NasdaqCM: RGLS) to Novartis AG. Under the terms of the proposed transaction, shareholders of Regulus will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect.

Related News